Bristol-Myers shares hit by decline of Yervoy melanoma drug

(Reuters) – Bristol-Myers Squibb Co reported disappointing second-quarter sales of its Yervoy melanoma treatment on Thursday, raising concerns about the long-term prospects for one of its most important cancer medicines and sending its shares lower.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *